Safety of sunitinib in patients with renal cell carcinoma following nephrectomy

被引：1

作者：

Heraudet, Luc ^{[1
]}

Domblides, Charlotte ^{[1
,2
]}

Daste, Amaury ^{[1
]}

Lefort, Felix ^{[1
]}

Bernhard, Jean-Christophe ^{[3
]}

Ravaud, Alain ^{[1
,2
]}

Gross-Goupil, Marine ^{[1
]}

机构：

[1] Bordeaux Univ Hosp, Dept Med Oncol, St Andre, France

[2] Univ Bordeaux, Bordeaux, France

[3] Bordeaux Univ Hosp, Dept Urol, Bordeaux, France

来源：

EXPERT OPINION ON DRUG SAFETY | 2020年 / 19卷 / 07期

关键词：

Sunitinib; clear cell carcinoma; metastatic; safety; adjuvant; HIGH-RISK; ADJUVANT SUNITINIB; SORAFENIB; MANAGEMENT; THERAPY; HYPERTENSION; MALATE; ASSURE;

D O I：

10.1080/14740338.2020.1774551

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction The safety profile characteristics of sunitinib were evaluated in patients who underwent nephrectomy for kidney cancer. Areas covered In this literature review, safety data were evaluated from phase III trials investigating sunitinib following nephrectomy, either in the more recent adjuvant setting after nephrectomy or in the metastatic setting, with a focus on new data from the CARMENA and SURTIME trials. In particular, the aim was to determine the specificity of toxicity in the adjuvant setting. Expert opinion In the adjuvant setting, even if the toxicity profile of sunitinib does not differ significantly from that in the metastatic setting, the importance of the dose intensity and, thus, exposure has been emphasized. Consequently, as described mainly in the metastatic setting, management of the adverse effects of sunitinib remains critical.

引用

页码：799 / 806

页数：8

共 41 条

[1]

[Anonymous], J CLIN ONCOL S

[2]

Barthelemy P, 2019, ANN ONCOL, V30

[3] Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects [J].

Bello, Carlo L. ;

Sherman, Laurie ;

Zhou, Jihao ;

Verkh, Lev ;

Smeraglia, John ;

Mount, Janessa ;

Klamerus, Karen J. .

ANTI-CANCER DRUGS, 2006, 17 (03) :353-358

[4] Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib The SURTIME Randomized Clinical Trial [J].

Bex, Axel ;

Mulders, Peter ;

Jewett, Michael ;

Wagstaff, John ;

van Thienen, Johannes V. ;

Blank, Christian U. ;

van Velthoven, Roland ;

Laguna, Maria del Pilar ;

Wood, Lori ;

van Melick, Harm H. E. ;

Aarts, Maureen J. ;

Lattouf, J. B. ;

Powles, Thomas ;

de Jong, Igle Jan ;

Rottey, Sylvie ;

Tombal, Bertrand ;

Marreaud, Sandrine ;

Collette, Sandra ;

Collette, Laurence ;

Haanen, John .

JAMA ONCOLOGY, 2019, 5 (02) :164-170

[5] Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma [J].

Bex, Axel ;

Albiges, Laurence ;

Ljungberg, Borje ;

Bensalah, Karim ;

Dabestani, Saeed ;

Giles, Rachel H. ;

Hofmann, Fabian ;

Hora, Milan ;

Kuczyk, Markus A. ;

Lam, Thomas B. ;

Marconi, Lorenzo ;

Merseburger, Axel S. ;

Fernandez-Pello, Sergio ;

Tahbaz, Rana ;

Abu-Ghanem, Yasmin ;

Staehler, Michael ;

Volpe, Alessandro ;

Powles, Thomas .

EUROPEAN UROLOGY, 2018, 74 (06) :805-809

[6] Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma [J].

Bhojani, Naeem ;

Jeldres, Claudio ;

Patard, Jean-Jacques ;

Perrotte, Paul ;

Suardi, Nazareno ;

Hutterer, Georg ;

Patenaude, Francois ;

Oudard, Stephane ;

Karakiewicz, Pierre I. .

EUROPEAN UROLOGY, 2008, 53 (05) :917-930

[7] Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis [J].

Bracarda, S. ;

Iacovelli, R. ;

Boni, L. ;

Rizzo, M. ;

Derosa, L. ;

Rossi, M. ;

Galli, L. ;

Procopio, G. ;

Sisani, M. ;

Longo, F. ;

Santoni, M. ;

Morelli, F. ;

Di Lorenzo, G. ;

Altavilla, A. ;

Porta, C. ;

Camerini, A. ;

Escudier, B. .

ANNALS OF ONCOLOGY, 2015, 26 (10) :2107-2113

[8] Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg 68, 2018) [J].

Casali, P. G. ;

Abecassis, N. ;

Aro, H. T. ;

Bauer, S. ;

Biagini, R. ;

Bielack, S. ;

Bonvalot, S. ;

Boukovinas, I. ;

Bovee, J. V. M. G. ;

Brodowicz, T. ;

Broto, J. M. ;

Buonadonna, A. ;

De Alava, E. ;

Tos, A. P. Dei ;

Del Muro, X. G. ;

Dileo, P. ;

Eriksson, M. ;

Fedenko, A. ;

Ferraresi, V. ;

Ferrari, A. ;

Ferrari, S. ;

Frezza, A. M. ;

Gasperoni, S. ;

Gelderblom, H. ;

Gil, T. ;

Grignani, G. ;

Gronchi, A. ;

Haas, R. L. ;

Hassan, B. ;

Hohenberger, P. ;

Issels, R. ;

Joensuu, H. ;

Jones, R. L. ;

Judson, I. ;

Jutte, P. ;

Kaal, S. ;

Kasper, B. ;

Kopeckova, K. ;

Krakorova, D. A. ;

Le Cesne, A. ;

Lugowska, I. ;

Merimsky, O. ;

Montemurro, M. ;

Pantaleo, M. A. ;

Piana, R. ;

Picci, P. ;

Piperno-Neumann, S. ;

Pousa, A. L. ;

Reichardt, P. ;

Robinson, M. H. .

ANNALS OF ONCOLOGY, 2018, 29 :267-267

[9] Systemic Therapy for Metastatic Renal-Cell Carcinoma [J].

Choueiri, Toni K. ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (04) :354-366

[10] Treatment selection in metastatic renal cell carcinoma: expert consensus [J].

Escudier, Bernard ;

Szczylik, Cezary ;

Porta, Camillo ;

Gore, Martin .

NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (06) :327-337

← 1 2 3 4 5 →